Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Biomarkers of systemic inflammation/nutritional status have been associated with outcomes in advanced-stage non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). However, most of them were not tested in cohorts of patients treated with ICIs in combination with chemotherapy (CT) (ICI + CT) or with CT alone, making it impossible to discriminate a predictive from a prognostic effect. We conducted a single-center retrospective study to search for associations between various baseline biomarkers/scores that reflected the systemic inflammation/nutritional status (Lung Immune Prognostic Index, Modified Lung Immune Prognostic Index, Scottish Inflammatory Prognostic Score, Advanced Lung Cancer Inflammation Index, EPSILoN, Prognostic Nutritional Index, Systemic Immune-Inflammation Index, Gustave Roussy Immune Score, Royal Marsden Hospital Prognostic Score, Lung Immuno-oncology Prognostic Score 3, Lung Immuno-oncology Prognostic Score 4, score published by Holtzman et al., and Glasgow Prognostic Score) and outcomes in metastatic NSCLC treated in a first-line setting either with ICI in monotherapy (cohort 1; n = 75), ICI + CT (cohort 2; n = 56), or CT alone (cohort 3; n = 221). In the three cohorts, the biomarkers/scores were moderately associated with overall survival (OS) and progression-free survival (PFS). Their prognostic performance was relatively poor, with a maximum c-index of 0.66. None of them was specific to ICIs and could help to choose the best treatment modality. The systemic inflammation/nutritional status, associated with outcomes independently of the treatment, is therefore prognostic but not predictive in metastatic NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 One-year overall survival (OS) and six-month progression-free survival (PFS) in the three cohorts, according to the scores based on biomarkers of systemic inflammation/nutritional status, analyzed as binary variables (high or low level). The numbers indicated in the squares represent the Kaplan–Meier estimation of the one-year OS or the six-month PFS. Abbreviations: ALI—Advanced Lung Cancer Inflammation Index [28], CT—chemotherapy alone, EPSILoN [32], GPS—Glasgow Prognostic Score [46], GRIm—Gustave Roussy Immune Score [33], Holtzman—score described by Holtzman et al. [36], ICI—ICI in monotherapy, ICI + CT—ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified Lung Immune Prognostic Index [30], PNI—Prognostic Nutritional Index [43], RMH—Royal Marsden Hospital Prognostic Score [45], SII—Systemic Immune-Inflammation Index [44], and SIPS—Scottish Inflammatory Prognostic Score [31].](https://figures.cochat.ai/paper-figures/4f77b0282ffa4b3093f33cab52694c60/systemic-inflammation-nutritional-status-scores-are-prognostic-but-not-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 2×
“After systemic inflammation has been proposed as a hallmark of cancer based on the fact that it promotes tumor development and dissemination [23,24], various studies have investigated the role of biomarkers of systemic inflammation in response to ICIs in patients suffering from advanced-stage NSCLC [25].”
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 1×
“Moreover, only 35% of the NSCLCs in cohorts 1 and 2 had a PD-L1 TPS <50%, which could be disturbing given that this proportion is generally estimated between 72 and 77% in the literature [63,64].”
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Moreover, only 35% of the NSCLCs in cohorts 1 and 2 had a PD-L1 TPS <50%, which could be disturbing given that this proportion is generally estimated between 72 and 77% in the literature [63,64].”
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Hu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · cited 2×
“Moreover, for tumors with a PD-L1 TPS ≥ 50%, there is currently no clear answer to whether the treatment should be ICIs in monotherapy or ICI + CT [18].”
[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients].
Onodera, T., Goseki, N., & Kosaki, G. (1984) · PubMed · Cited by 1,688
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 1×
“Previous studies have also suggested that some genetic alterations in the tumor cells, such as somatic mutations in serine/threonine kinase 11 (STK11) or in kelch-like ECH-associated protein 1 (KEAP1), could serve as biomarkers to predict responses to ICIs in NSCLC [20,21].”
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,163
Systemic inflammation, nutritional status and survival in patients with cancer
McMillan, D. C. (2009) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32832a7902 · Cited by 1,001 · cited 1×
“It is now well established that systemic inflammation plays a critical role in many phases of cancer development, influences responses to therapies, and is involved in cancer cachexia, which is itself a poor prognostic factor [24,48].”
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913 · cited 7×
“[36], HR—hazard ratio, ICI—cohort of patients treated with ICI in monotherapy, ICI + CT—cohort of patients treated with ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified…”
InfluentialQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837 · cited 1×
“One reason explaining this imperfection could be the heterogeneous expression of PD-L1 within the tumors and through time and treatment lines [16,17].”
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L. V., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 738
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.028 · Cited by 599
McMillan, D. C. (2008) · Proceedings of the Nutrition Society · doi:10.1017/s0029665108007131 · Cited by 472 · cited 13×
“Abbreviations: ALI—Advanced Lung Cancer Inflammation Index [28], D—dichotomized scores, EPSILoN [32], GPS—Glasgow Prognostic Score [46], GRIm—Gustave Roussy Immune Score [33], Holtzman—score described by Holtzman et al.”
InfluentialNishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., Longeras, P. D., Goldschmidt, J., Novello, S., Orlandi, F., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.025 · Cited by 458
Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis
Yang, R., Chang, Q., Meng, X., Gao, N., & Wang, W. (2018) · Journal of Cancer · doi:10.7150/jca.25691 · Cited by 441 · cited 1×
“The same link has also been described in extra-thoracic malignancies, such as diffuse large B-cell lymphoma, melanoma, colorectal, head and neck, liver, prostate, or renal cancers [53,54].”
Jafri, S. H., Shi, R., & Mills, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-158 · Cited by 389 · cited 21×
“Sci. 2023, 24, 3618 3 of 17 available, such as hemogram, albumin, C-reactive protein (CRP), lactate dehydrogenase (LDH), or body mass index (BMI) [25,27,28].”
InfluentialRicciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1981 · Cited by 378 · cited 3×
“The authors also suggested that a very high TMB level could be used to select patients with PD-L1-positive NSCLC who would benefit from ICIs in monotherapy with no need to add CT [19].”
InfluentialLiu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364 · cited 9×
“Sci. 2023, 24, 3618 11 of 17 mation/nutritional status and outcomes in patients treated with ICIs, such as those that evaluated the Scottish Inflammatory Prognostic Score (SIPS) [31], EPSILoN [32,56,57], the Prognostic Nutritional Index (PNI) [58–61], the SII [39], the Gustave Roussy Immune score (GRIm) [33,34], the R…”
InfluentialAntonia, S. J., Borghaei, H., Ramalingam, S. S., Horn, L., De Castro Carpeño, J., Pluzanski, A., Burgio, M. A., Garassino, M., Chow, L. Q. M., Gettinger, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30407-3 · Cited by 351
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz288 · Cited by 338 · cited 1×
“It has also been reported that, compared to high PD-L1 TPS (≥50%), very high PD-L1 TPS (≥90%) was associated with even better outcomes in patients treated with ICIs in monotherapy, suggesting that the higher the PD-L1 expression, the better the response [15].”
Herbst, R. S., Garon, E. B., Kim, D.-W., Cho, B. C., Gervais, R., Perez-Gracia, J. L., Han, J.-Y., Majem, M., Forster, M. D., Monnet, I., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.001 · Cited by 320
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K.-H., Xin, C.-F., Hong, M. H., Ahn, B.-C., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 282 · cited 1×
“Indeed, while up to 15% of patients can benefit from long-term survival (rarely seen before the era of ICIs) [9–12], some do not respond or even suffer from a dramatic hyperprogression [13].”
Bigot, F., Castanon, E., Baldini, C., Hollebecque, A., Carmona, A., Postel-Vinay, S., Angevin, E., Armand, J.-P., Ribrag, V., Aspeslagh, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.027 · Cited by 235 · cited 10×
“Abbreviations: ALI—Advanced Lung Cancer Inflammation Index [28], D—dichotomized scores, EPSILoN [32], GPS—Glasgow Prognostic Score [46], GRIm—Gustave Roussy Immune Score [33], Holtzman—score described by Holtzman et al.”
InfluentialKazandjian, D., Gong, Y., Keegan, P., Pazdur, R., & Blumenthal, G. M. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1747 · Cited by 235 · cited 1×
“Another pooled analysis of 5 randomized trials evaluating ICIs versus CT only and 6 randomized trials evaluating targeted therapies (TTs) versus other TTs or CT only concluded also that the LIPI was prognostic in all the cohorts (1368 patients treated with ICIs and 1072 patients treated with CT only for the trials eva…”
Papillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J., & Walsh, A. M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000706 · Cited by 235 · cited 4×
“Previous studies have also suggested that some genetic alterations in the tumor cells, such as somatic mutations in serine/threonine kinase 11 (STK11) or in kelch-like ECH-associated protein 1 (KEAP1), could serve as biomarkers to predict responses to ICIs in NSCLC [20,21].”
InfluentialMantzorou, M., Koutelidakis, A., Theocharis, S., & Giaginis, C. (2017) · Nutrition and Cancer · doi:10.1080/01635581.2017.1367947 · Cited by 216 · cited 1×
“Similarly, because the nutritional status can impact the response to treatment in various malignancies, biomarkers of the nutritional status have also been developed [26].”
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193 · cited 8×
“After systemic inflammation has been proposed as a hallmark of cancer based on the fact that it promotes tumor development and dissemination [23,24], various studies have investigated the role of biomarkers of systemic inflammation in response to ICIs in patients suffering from advanced-stage NSCLC [25].”
InfluentialArkenau, H.-T., Olmos, D., Ang, J. E., de Bono, J., Judson, I., & Kaye, S. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604218 · Cited by 189 · cited 10×
“[36], HR—hazard ratio, ICI—cohort of patients treated with ICI in monotherapy, ICI + CT—cohort of patients treated with ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified…”
InfluentialSheng, J., Fang, W., Yu, J., Chen, N., Zhan, J., Ma, Y., Yang, Y., Huang, Y., Zhao, H., & Zhang, L. (2016) · Scientific Reports · doi:10.1038/srep20090 · Cited by 188 · cited 1×
“One reason explaining this imperfection could be the heterogeneous expression of PD-L1 within the tumors and through time and treatment lines [16,17].”
Gu, X.-B., Tian, T., Tian, X.-J., & Zhang, X.-J. (2015) · Scientific Reports · doi:10.1038/srep12493 · Cited by 178
Shoji, F., Takeoka, H., Kozuma, Y., Toyokawa, G., Yamazaki, K., Ichiki, M., & Takeo, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.006 · Cited by 138
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 118
Wang, Y., Li, Y., Chen, P., Xu, W., Wu, Y., & Che, G. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.116 · Cited by 117
Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis
Li, D., Yuan, X., Liu, J., Li, C., & Li, W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.51 · Cited by 112
Mountzios, G., Samantas, E., Senghas, K., Ζervas, Ε., Krisam, J., Samitas, Κ., Bozorgmehr, F., Kuon, J., Agelaki, S., Baka, S., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100254 · Cited by 109 · cited 9×
“Sci. 2023, 24, 3618 3 of 17 available, such as hemogram, albumin, C-reactive protein (CRP), lactate dehydrogenase (LDH), or body mass index (BMI) [25,27,28].”
InfluentialAggarwal, C., Thompson, J. C., Chien, A. L., Quinn, K. J., Hwang, W.-T., Black, T. A., Yee, S. S., Christensen, T. E., LaRiviere, M. J., Silva, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3663 · Cited by 102 · cited 1×
“Previous studies have also suggested that some genetic alterations in the tumor cells, such as somatic mutations in serine/threonine kinase 11 (STK11) or in kelch-like ECH-associated protein 1 (KEAP1), could serve as biomarkers to predict responses to ICIs in NSCLC [20,21].”
Sorich, M. J., Rowland, A., Karapetis, C. S., & Hopkins, A. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.006 · Cited by 101
Prelaj, A., Ferrara, R., Rebuzzi, S. E., Proto, C., Signorelli, D., Galli, G., Toma, A. D., Randon, G., Pagani, F., Viscardi, G., et al. (2019) · Cancers · doi:10.3390/cancers11121954 · Cited by 84 · cited 7×
“Sci. 2023, 24, 3618 11 of 17 mation/nutritional status and outcomes in patients treated with ICIs, such as those that evaluated the Scottish Inflammatory Prognostic Score (SIPS) [31], EPSILoN [32,56,57], the Prognostic Nutritional Index (PNI) [58–61], the SII [39], the Gustave Roussy Immune score (GRIm) [33,34], the R…”
InfluentialHu, Y., Shen, J., Liu, R., Feng, Z., Zhang, C., Ling, L., & Chen, L. (2018) · The International Journal of Biological Markers · doi:10.1177/1724600818799876 · Cited by 79
Prelaj, A., Rebuzzi, S. E., Pizzutilo, P., Bilancia, M., Montrone, M., Pesola, F., Longo, V., Bene, G. D., Lapadula, V., Cassano, F., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.017 · Cited by 75
Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis
Hua, X., Chen, J., Wu, Y., Sha, J., Han, S., & Zhu, X. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1725-2 · Cited by 71 · cited 1×
“The same link has also been described in extra-thoracic malignancies, such as diffuse large B-cell lymphoma, melanoma, colorectal, head and neck, liver, prostate, or renal cancers [53,54].”
Stares, M., Ding, T.-E., Stratton, C., Thomson, F., Baxter, M. A., Cagney, H. P., Cumming, K., Swan, A. M., Ross, F., Barrie, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100445 · Cited by 71 · cited 10×
“[36], HR—hazard ratio, ICI—cohort of patients treated with ICI in monotherapy, ICI + CT—cohort of patients treated with ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified…”
InfluentialMinami, S., Ihara, S., Ikuta, S., & Komuta, K. (2019) · World Journal of Oncology · doi:10.14740/wjon1193 · Cited by 70
Matsubara, T., Takamori, S., Haratake, N., Toyozawa, R., Miura, N., Shimokawa, M., Yamaguchi, M., Seto, T., & Takenoyama, M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.02.27 · Cited by 70
Banna, G. L., Cortellini, A., Cortinovis, D. L., Tiseo, M., Aerts, J. G. J. V., Barbieri, F., Giusti, R., Bria, E., Grossi, F., Pizzutilo, P., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100078 · Cited by 66 · cited 7×
“[36], HR—hazard ratio, ICI—cohort of patients treated with ICI in monotherapy, ICI + CT—cohort of patients treated with ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified…”
InfluentialLiu, N., Jiang, A., Zheng, X., Fu, X., Zheng, H., Gao, H., Wang, J., Liang, X., Tian, T., Ruan, Z., et al. (2021) · Journal of Cancer · doi:10.7150/jca.55936 · Cited by 61
Lenci, E., Cantini, L., Pecci, F., Cognigni, V., Agostinelli, V., Mentrasti, G., Lupi, A., Ranallo, N., Paoloni, F., Rinaldi, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051005 · Cited by 51 · cited 1×
“Finally, while some studies reported interest in evaluating biomarkers/scores after treatment initiation [65,66], we decided to focus only on pre-treatment values as it is at baseline that physicians have to choose the first-line therapeutic modality.”
Tanaka, S., Uchino, J., Yokoi, T., Kijima, T., Gotô, Y., Suga, Y., Katayama, Y., Nakamura, R., Morimoto, K., Nakao, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020423 · Cited by 40
Kasahara, N., Sunaga, N., Tsukagoshi, Y., Miura, Y., SAKURAI, R., Kitahara, S., Yokobori, T., Kaira, K., Mogi, A., Maeno, T., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13262 · Cited by 37 · cited 10×
“Sci. 2023, 24, 3618 11 of 17 mation/nutritional status and outcomes in patients treated with ICIs, such as those that evaluated the Scottish Inflammatory Prognostic Score (SIPS) [31], EPSILoN [32,56,57], the Prognostic Nutritional Index (PNI) [58–61], the SII [39], the Gustave Roussy Immune score (GRIm) [33,34], the R…”
InfluentialWang, W., Huang, Z., Yu, Z., Zhuang, W., Zheng, W., Cai, Z., Shi, L., Yu, X., Lou, G., Hong, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572853 · Cited by 30
Holtzman, L., Moskovitz, M. T., Urban, D., Nechushtan, H., Keren, S., Reinhorn, D. J., Wollner, M., Daher, S., Rottenberg, Y., Rovitzky, Y., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.12.006 · Cited by 26 · cited 9×
“[36], HR—hazard ratio, ICI—cohort of patients treated with ICI in monotherapy, ICI + CT—cohort of patients treated with ICI in combination with chemotherapy, LIPI—Lung Immune Prognostic Index [29], LIPS-3—Lung Immuno-oncology Prognostic Score 3 [35], LIPS-4—Lung Immuno-oncology Prognostic Score 4 [35], mLIPI—Modified…”
InfluentialXie, J., Zang, Y., Liu, M., Peng, L.-L., & Zhang, H. (2021) · Oncology Research and Treatment · doi:10.1159/000514443 · Cited by 13 · cited 1×
“A meta-analysis published a few years later finally concluded that the LIPI was prognostic, independent of the treatment [55].”
Moor, R., Roberts, K. E., Mason, R., Ladwa, R., Lwin, Z., Hughes, B. G. M., & O'Byrne, K. J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.834 · Cited by 7
Descourt, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.332 · Cited by 5 · cited 1×
“We hope that the results of prospective randomized trials, such as the PERSEE trial evaluating pembrolizumab versus pembrolizumab in combination with CT in advanced-stage NSCLC with PD-L1 TPS ≥50%, will provide some answers [72].”
Cipriano, É., Magalhães, H., Estevinho, F., & Sottomayor, C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz447.017 · Cited by 4
Prelaj, A., Rebuzzi, S. E., Pizzutilo, P., Montrone, M., Pesola, F., Longo, V., Lapadula, V., Cassano, F., Petrillo, P., Bafunno, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy493.005 · Cited by 3 · cited 7×
“Sci. 2023, 24, 3618 11 of 17 mation/nutritional status and outcomes in patients treated with ICIs, such as those that evaluated the Scottish Inflammatory Prognostic Score (SIPS) [31], EPSILoN [32,56,57], the Prognostic Nutritional Index (PNI) [58–61], the SII [39], the Gustave Roussy Immune score (GRIm) [33,34], the R…”
InfluentialDennehy, C., McMahon, E., Power, D. G., O’Reilly, S., Collins, D. C., O’Mahony, D., Horgan, A. M., O’Connor, M., Jordan, E., Calvert, P. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e20704 · Cited by 3
Sibille, A., Bustin, F., Carestia, L., Catala, G., Compère, C., Cuppens, K., Colinet, B., Coulon, S., Brucker, N. D., Decoster, L., et al. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2063700 · Cited by 1 · cited 1×
“Currently, in these cases, physicians rely on clinical and/or pathological/molecular characteristics to choose between the two treatment modalities [62].”
Self-citationHarrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Ancel, J., Dormoy, V., Nawrocki‐Raby, B., Dalstein, V., Durlach, A., Dewolf, M., Gilles, C., Polette, M., & Deslée, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171649 · Cited by 40
“Their results supported that systemic inflammation/nutritional status could be associated with the outcomes independently of the treatment, and were therefore prognostic but not predictive (59).”
ResultYamaguchi, O., Kaira, K., Imai, H., Mouri, A., Shiono, A., Miura, Y., Hashimoto, K., Kobayashi, K., & Kagamu, H. (2023) · Oncology · doi:10.1159/000534169 · Cited by 21
Nguyen, C. T. T., Van, T. N. K., & Huong, P. T. (2024) · Cancer Control · doi:10.1177/10732748241285474 · Cited by 26
Ito, K., Hashimoto, K., Kaira, K., Yamaguchi, O., Mouri, A., Shiono, A., Miura, Y., Kobayashi, K., Imai, H., Kuji, I., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14243 · Cited by 11
Lee, K. H., Lee, J.-S., Sugawara, S., Kang, J., Kim, H. R., Inui, N., Hida, T., Yoshida, T., Tanaka, H., Yang, C., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108109 · Cited by 16
Metadata
- Authors
- Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., & Ocak, S.
- Affiliations
- UCLouvain (BE)
- CHU Dinant Godinne UCL Namur (BE)
- Pathology Department, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Radiology Division, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Nuclear Medicine Division, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Thoracic Surgery Department, CHU UCL Namur (Godinne Site), UCLouvain, Avenue Docteur G. Thérasse 1, 5530 Yvoir, Belgium
- Corresponding author
- Ocak, Sebahat
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-02-10
- Volume
- 24
- Issue
- 4
- Pages
- 3618
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9966997
- OpenAlex
- W4320493683
- Cited by
- 23
- References
- 73
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 6 · 2023: 3
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- metastatic non-small cell lung cancer, immune checkpoint inhibitors, systemic inflammation, nutritional status, prognostic factors, prognostic score, first-line therapy, chemotherapy, overall survival, progression-free survival, immune-related adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Inflammation, Lung Neoplasms, Nutritional Status, Prognosis, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.